 |
54 Diseases |  |
8 Trials |
|
8 Trials |  |
2662 News |  |
| «12345678910111213...2324» |
- Mycobutin (rifabutin) / Pfizer, Lupin
Successful, Concurrent Treatment of a Patient with Pulmonary Tuberculosis and Hepatitis C Infection Using Therapeutic Drug Monitoring (Room 207-208 (South Building, Level 2), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_5360;
have developed a method to measure the DAA levels of ledipasvir and sofosbuvir (LDV/SOF) in blood...Sputum samples were smear positive for acid fast bacilli (AFB) and culture positive for Mycobacterium Tuberculosis (MTB) with a positive MTB polymerase chain reaction and no mutations for isoniazid or rifampin resistance on molecular analysis...This case illustrates the successful, simultaneous use of LDV/SOF and rifabutin in HCV/TB coinfection with significant public health implications. More robust research will determine if this treatment method is generalizable.
- || ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal, HEOR: "If I Get Cured, My Whole Quality of Life Will Change": Patients' Anticipated and Actualized Benefits Following Cure from Chronic Hepatitis C. (Pubmed Central) - Feb 17, 2022
Highly interconnected effects on quality of life worked synergistically through improved physical and psychological well-being. Stakeholders should appreciate the multi-dimensional benefits that viral eradication bestows upon individuals and society.
- | ledipasvir/sofosbuvir / Generic mfg.
Journal: Assessment of outcome for sample of Iraqi patients with chronic hepatitis C virus infection treated by Ledipasvir/sofosbuvir drug. (Pubmed Central) - Feb 15, 2022
Excellent therapeutic results were achieved with generic combination of sofosbuvir/ledipasvir. The regimen is highly effective and tolerable with the highest viral response observed in HCV patients with genotype 1and 4, inclusive of patients with chronic renal failure or cirrhosis.
- || ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal, Real-world evidence: Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective? (Pubmed Central) - Feb 12, 2022
The present real-world data of 525 patients with HCV genotypes 1, 1a, 1b, 3, 4, and 5 who underwent SOF/LDV ± RBV treatment in Turkey demonstrated a high efficacy and safety profile. HCV GT2 patients should be treated with more efficacious treatment.
- | daclatasvir/sofosbuvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Journal: Impact of sofosbuvir/ledipasvir versus sofosbuvir/daclatasvir regimens on the male sexual function of patients with chronic hepatitis C. (Pubmed Central) - Feb 12, 2022
Both treatment regimens were associated with the improvement of erectile function and sex hormonal milieu. SOF/daclatasvir was associated with earlier improvement of erectile function compared with SOF/ledipasvir.
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Journal: Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison. (Pubmed Central) - Feb 10, 2022
SOF/daclatasvir was associated with earlier improvement of erectile function compared with SOF/ledipasvir. Outreach mass screening followed by immediate onsite treatment with a simplified pangenotypic DAA regimen, sofosbuvir/velpatasvir, provides successful strategies toward HCV micro-elimination among prisoners.
- | Zepatier (grazoprevir/elbasvir) / Merck (MSD), Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Journal: Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. (Pubmed Central) - Feb 9, 2022
Outreach mass screening followed by immediate onsite treatment with a simplified pangenotypic DAA regimen, sofosbuvir/velpatasvir, provides successful strategies toward HCV micro-elimination among prisoners. While risk of incident ALT elevations was increased among PI-based DAA initiators in both FIB-4 groups, risk of severe hepatic dysfunction and hepatic decompensation did not differ between PI and non-PI-based DAA initiators in either FIB-4 group.
- || ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal: Beta-Thalassemia Major alters Sofosbuvir/Ledipasvir exposure in Hepatitis-C virus Infected Adolescent Patients. (Pubmed Central) - Feb 8, 2022
P3
The identified systematically lower drug exposure in BTM patients might partially, explain relapses or treatment failures among BTM patients reported in other studies. BTM may be a hurdle towards implementing HCV micro-elimination model that may necessitate dose-adjustment.
- Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Technivie (ombitasvir/paritaprevir/ritonavir) / AbbVie
TREATMENT WITH SOF/VEL/VOX IN HIV/HCV-COINFECTED PATIENTS PREVIOUSLY EXPOSED TO DAAs ([VIRTUAL]) - Feb 7, 2022 - Abstract #CROI2022CROI_1126;
Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is a pan-genotypic direct active antiviral (DAA) regimen approved for patients who have previously failed anti-HCV treatment with other DAAs...The type of previous regimens included sofosbuvir/ledipasvir in 50% patients, ombitasvir/paritaprevir/ritonavir plus dasabuvir in 9.4%, sofosbuvir plus daclatasvir in 9.4%, elbasvir/grazoprevir in 9.4%, glecaprevir/pibrentasvir in 9.4% and 13.4% other regimens...Liver cirrhosis and genotype did not influence treatment response (SVR by ITT 90% for cirrhosis and 85.8% for G3). Our findings suggest that SOF/VEL/VOX is a highly effective regimen for treatment of coinfected patients previously failing to DAA regimens, across all genotypes and in the presence of cirrhosis.
- || ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal: Ledipasvir/Sofosbuvir Eradicates Hepatitis C in an Immunodeficient STAT3-GOF Patient. (Pubmed Central) - Feb 4, 2022
Our findings suggest that SOF/VEL/VOX is a highly effective regimen for treatment of coinfected patients previously failing to DAA regimens, across all genotypes and in the presence of cirrhosis. No abstract available
- || ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal: One-Year Outcomes after Ledipasvir/Sofosbuvir Treatment of Chronic Hepatitis C in Teenagers with and without Significant Liver Fibrosis-A Case Series Report. (Pubmed Central) - Feb 3, 2022
A one-year observation of teenagers with CHC and significant fibrosis treated with LDV/SOF revealed that regression of liver fibrosis is possible, but not certain. Further observations in larger groups of patients are necessary to find predictors of liver fibrosis regression.
- ||| Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead
Trial completion: A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection (clinicaltrials.gov) - Feb 2, 2022
P=N/A, N=1609, Completed, Sponsor: Gilead Sciences
Further observations in larger groups of patients are necessary to find predictors of liver fibrosis regression. Active, not recruiting --> Completed
- || ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal: Acute Renal Failure in a Patient on Ledipasvir-Sofosbuvir Therapy for Hepatitis C. (Pubmed Central) - Jan 27, 2022
Active, not recruiting --> Completed No abstract available
- || Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Clinical, Reimbursement, Journal, Medicare: Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D. (Pubmed Central) - Jan 20, 2022
The results of this cross-sectional study suggest that authorized generic drugs for insulin and direct-acting antiviral agents may lower out-of-pocket spending for patients but are unlikely to provide savings for Part D plans or Medicare. Instead, these drugs allow manufacturers to offer products at a lower list price without materially lowering net prices or profits.
- | ledipasvir/sofosbuvir / Generic mfg.
Journal: Effective Treatment of Chronic Hepatitis C Virus Infection With Ledipasvir/Sofosbuvir in 2 Teenagers With HIV Coinfection: A Brief Report. (Pubmed Central) - Jan 19, 2022
Both patients achieved a sustained virologic response 12 weeks after the end of treatment. No serious adverse effects were reported.
- || Zepatier (grazoprevir/elbasvir) / Merck (MSD)
Clinical, Journal: A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: THE PRIORITIZE STUDY. (Pubmed Central) - Jan 15, 2022
P4
Overall, the two regimens were equivalent in effectiveness. The results support current HCV guidelines that do not distinguish between ribavirin-free EBR/GZR or LDV/SOF.
- | ribavirin / Generic mfg.
Journal: The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals. (Pubmed Central) - Jan 15, 2022
In the real-world setting, sofosbuvir-based treatment is safe, effective, and well tolerated in AN/AI patients. Sustained virologic response was high regardless of HCV genotype or cirrhosis status.
- || ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal: Responsible Inclusion of Pregnant Individuals in Eradicating Hepatitis C Virus. (Pubmed Central) - Jan 13, 2022
Our systematic review of publications on HCV treatment with DAAs in pregnancy revealed only one interventional study, which evaluated sofosbuvir/ledipasvir in 8 pregnant individuals...The exclusion of pregnant individuals without justification denies them and their offspring access to potential health benefits, raising justice concerns considering growing data on DAA safety and global efforts to promote equitable and comprehensive HCV eradication. Finally, we propose a path forward for research and treatment programs during pregnancy to help advance the goal of HCV elimination.
- || Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Sovaldi (sofosbuvir) / Gilead
Enrollment closed: A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials (clinicaltrials.gov) - Jan 11, 2022
P=N/A, N=461, Active, not recruiting, Sponsor: Gilead Sciences
Finally, we propose a path forward for research and treatment programs during pregnancy to help advance the goal of HCV elimination. Enrolling by invitation --> Active, not recruiting
- || Technivie (ombitasvir/paritaprevir/ritonavir) / AbbVie
Clinical, Journal, Real-world evidence: Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience. (Pubmed Central) - Dec 25, 2021
They were associated with a significant improvement in the hematologic, hepatic, and renal biochemical profiles. The baseline AST, liver cirrhosis, and treatment regimen might have an impact on achieving SVR.
- | Zepatier (grazoprevir/elbasvir) / Merck (MSD), Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Journal: Identification and management of contraindicated drug-drug interactions through pharmaceutical care programs: Experience in direct-acting antivirals therapy. (Pubmed Central) - Dec 23, 2021
The baseline AST, liver cirrhosis, and treatment regimen might have an impact on achieving SVR. The implementation of pharmaceutical care programs in DAA therapy provides a favorable outcome and substantial cost avoidance.
- | ribavirin / Generic mfg.
Journal: Outcomes using direct-acting antiviral hepatitis-C treatment in older versus younger Veterans. (Pubmed Central) - Dec 23, 2021
The implementation of pharmaceutical care programs in DAA therapy provides a favorable outcome and substantial cost avoidance. LED/SOF was a well-tolerated and effective regimen in an older Veteran population despite their multiple comorbidities and polypharmacy presence.
- || atorvastatin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Clinical, PK/PD data, Journal: Pharmacokinetic interaction between atorvastatin and fixed-dose combination of sofosbuvir/ledipasvir in healthy male Egyptian volunteers. (Pubmed Central) - Dec 22, 2021
After concurrent administration of FDCSL with atorvastatin, the AUC of both atorvastatin and sofosbuvir were increased. Caution should be taken with close monitoring for possible side effects after co-administration of atorvastatin and FDCSL in clinical practice.
- || ribavirin / Generic mfg.
Clinical, Journal: Direct-Acting Antivirals in the Treatment of Hepatitis C Virus Recurrence after Liver Transplantation: Real-life Experience in a Mexican Cohort. (Pubmed Central) - Dec 16, 2021
Caution should be taken with close monitoring for possible side effects after co-administration of atorvastatin and FDCSL in clinical practice. In a Mexican cohort, DAA therapy in LT patients with recurrence of HCV infection showed high efficacy and an acceptable safety profile.
- | ledipasvir/sofosbuvir / Generic mfg.
Journal: Innovative derivative/zero ratio spectrophotometric method for simultaneous determination of sofosbuvir and ledipasvir: Application to average content and uniformity of dosage units. (Pubmed Central) - Dec 16, 2021
This original method was validated according to ICH requirements and statistically compared to published comparison methods. This method was applied to estimate the average content and the uniformity of dosage units of SOF/LED combined dosage form according to British Pharmacopeia requirements.
- ||| ribavirin / Generic mfg.
Clinical, Journal, Adverse events: Efficacy of antiviral therapy in patients with post-hepatitis C liver cirrhosis: is hyperuricaemia a potential adverse effect? (Pubmed Central) - Nov 29, 2021
SOF+LDV and SOF+DACLA plus ribavirin regimens are highly effective in treating chronic HCV patients with compensated liver cirrhosis. Hyperuricaemia is considered a potential adverse effect to DAAS containing ribavirin and may lead to serious side effects such as renal impairment.
- | ledipasvir/sofosbuvir / Generic mfg.
Journal: Acute hepatitis C virus infection and direct-acting antiviral drugs: Perfect combination to eliminate the epidemic? (Pubmed Central) - Nov 29, 2021
DAA regimens were SOF/LDV (19 episodes), SOF/VEL (14), ELB/GZV (5) and GLP/PIB (2)...In conclusion, early treatment with DAA in AHC patients proved effective and safe. It could be an excellent strategy to eliminate HCV infection in HIV-coinfected MSM.
- ||| ledipasvir/sofosbuvir / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea (clinicaltrials.gov) - Nov 29, 2021
P=N/A, N=1081, Completed, Sponsor: Gilead Sciences
It could be an excellent strategy to eliminate HCV infection in HIV-coinfected MSM. Recruiting --> Completed | N=3000 --> 1081 | Trial completion date: Jan 2022 --> Jun 2021 | Trial primary completion date: Jan 2022 --> Jun 2021
- || Zepatier (grazoprevir/elbasvir) / Merck (MSD), Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Clinical, Journal, HEOR: Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C. (Pubmed Central) - Nov 24, 2021
Recruiting --> Completed | N=3000 --> 1081 | Trial completion date: Jan 2022 --> Jun 2021 | Trial primary completion date: Jan 2022 --> Jun 2021 Overall, SOF/VEL and LDV/SOF regimens are more likely to be cost-effective among various subgroups of Chinese patients with CHC.
- || Clinical, Journal: Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub Saharan Africa and South East Asia. (Pubmed Central) - Nov 17, 2021
This study also shows the ineffectiveness of the first generation NS5A inhibitors against 6u and 6v, and confirms the inherent resistance of 3b and 3g to most NS5A inhibitors. Clinical studies to confirm in vivo sensitivity to NS5A inhibitors are urgently needed so that rational, effective treatment strategies may be developed for unusual subtypes.
- || ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal: Ledipasvir/sofosbuvir-associated photosensitivity in a case with chronic hepatitis C. (Pubmed Central) - Nov 6, 2021
The most common adverse events associated with DAAs are fatigue and headache, but various abnormal cutaneous effects including photosensitivity have been reported, especially with the use of simeprevir/sofosbuvir. Here we present a case developing photosensitivity due to ledipasvir/sofosbuvir during the treatment of chronic hepatitis C.
- | ledipasvir/sofosbuvir / Generic mfg.
Journal: Treating Hepatitis C Virus Reinfection With 8 Weeks of Ledipasvir/Sofosbuvir Achieves Sustained Virologic Response. (Pubmed Central) - Nov 6, 2021
Here we present a case developing photosensitivity due to ledipasvir/sofosbuvir during the treatment of chronic hepatitis C. Three patients reinfected with hepatitis C virus after a sustained virologic response were considered treatment naïve and treated with a short-course direct acting antiviral regimen.
- || Arbidol (umifenovir) / Pharmstandard, Prezcobix (darunavir/cobicistat) / Gilead, J&J, Xofluza (baloxavir marboxil) / Roche, Shionogi
Clinical, Review, Journal: Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials. (Pubmed Central) - Nov 4, 2021
Further larger RCTs in other countries are warranted to support these findings. In contrast, the present findings of limited RCTs did not indicate the use of lopinavir/ritonavir, sofosbuvir/ledipasvir, baloxavir, umifenovir, and darunavir/cobicistat in the treatment of patients hospitalized for COVID-19.
- || Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead
Trial completion date, Trial primary completion date: A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection (clinicaltrials.gov) - Nov 3, 2021
P=N/A, N=1609, Active, not recruiting, Sponsor: Gilead Sciences
In contrast, the present findings of limited RCTs did not indicate the use of lopinavir/ritonavir, sofosbuvir/ledipasvir, baloxavir, umifenovir, and darunavir/cobicistat in the treatment of patients hospitalized for COVID-19. Trial completion date: Jan 2023 --> Dec 2021 | Trial primary completion date: Jan 2023 --> Dec 2021
- | ledipasvir/sofosbuvir / Generic mfg.
Journal: Hepatitis C Resistance-Associated Substitutions Among People Who Inject Drugs Treated With Direct-Acting Antiviral-Containing Regimens. (Pubmed Central) - Oct 27, 2021
Among the 11 participants who had posttreatment samples with detectable virus (7 treatment failures, 1 late relapse, 3 reinfections), 1 sofosbuvir/ledipasvir failure had a baseline H58P...Only 2 of 150 (1.3%) in our longitudinal cohort developed treatment-emergent RASs. Concern for transmission of resistant virus may therefore be minimal.
- | ledipasvir/sofosbuvir / Generic mfg.
New P2 trial: Treatment of Chronic Hepatitis C Infection by Ledipasvir/Sofosbuvir in Na (clinicaltrials.gov) - Oct 24, 2021
P2, N=50, Completed, Sponsor: Mansoura University Children Hospital
- Daklinza (daclatasvir) / BMS
[VIRTUAL] UPTAKE OF DIRECT ACTING ANTIVIRALS FOR TREATMENT OF CHILDREN AND ADOLESCENTS WITH HEPATITIS C IN RUSSIA () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1221;
However, some responding clinics have yet to start treating paediatric patients with DAAs . Reasons for this, including potential barriers, need to be explored to facilitate treatment access for children and adolescents .
- pibrentasvir (ABT-530) / AbbVie
[VIRTUAL] TREATMENT OF HEPATITIS C RECURRENCE POST LIVER TRANSPLANT WITH ORAL DIRECT ACTING ANTI-VIRAL: A REAL-WORLD EXPERIENCE FROM A SATELLITE CLINIC IN THE SOUTHERN UNITED STATES () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1220;
Excellent graft survival at 1 and 3 years post LT was noted . Reported side effects were mild and well tolerated .
- entecavir / Generic mfg.
[VIRTUAL] ROLE OF ENTECAVIR IN PREVENTING CLINICAL REACTIVATION OF HBV IN HCV/HBV CO-INFECTED PATIENTS RECEIVING DAA THERAPY FOR CHRONIC HEPATITIS () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1214;
After stopping ETV treatment, the HBVr occurred in a substantial proportion of patients. Prophylactic ETV might consider to co-administer with DAA in HBV/HCV co-infected patients.
- voxilaprevir (GS-9857) / Gilead, Opdivo (nivolumab) / Ono Pharma, BMS, Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] MINIMAL DRUG-DRUG INTERACTIONS BETWEEN DIRECT- ACTING ANTIVIRALS AND HCC TREATMENTS – A TERRITORY- WIDE COHORT STUDY () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1206;
More data concerning DDI between immunotherapy and DAA would be helpful to guide the best DAA and HCC treatments for the patients . Table .
- [VIRTUAL] DIRECT ANTIVIRALS CAN ACHIEVE A CURE IN ALL PATIENTS WITH CHRONIC HEPATITIS C DUE TO GENOTYPE 5. (FRENCH MULTICENTRE STUDY.) () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1188;
A high SVR12, 99% (138/139) in intention to treat and 100% (138/138) per protocol, was achieved in HCV GT5 patients treated with a DAA-regimen . This cohort shows that the combination treatments of SOF/LDV, SOF/VEL and GLE/PIB are very efficient in patients infected with HCV GT5.
- Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
[VIRTUAL] REAL-WORLD EFFECTIVENESS AND SAFETY OF INTERFERON-FREE DAAS FOR 14,676 HEPATITIS C (CHC) PATIENTS WITH GENOTYPES 1, 2, 3, 4 AND 6: A MULTINATIONAL STUDY () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1179;
In this diverse multinational real-world cohort of patients with genotypes 1, 2, 3, 4 and 6, the overall cure rate was 96.7%, despite large numbers of cirrhosis, HCC, prior treatment failure, GT3/6 and use of older DAA . SVR12 in GT3/6 patients with cirrhosis and TE was relatively lower but still excellent at about 90%.
- Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
[VIRTUAL] REAL-WORLD EFFECTIVENESS AND FACTORS ASSOCIATED WITH SVR12 IN A DIVERSE POPULATION OF HCV INFECTED PERSONS FROM FOUR LARGE EUROPEAN COHORTS () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1171;
We observed a gradual decrease in SVR12 with increasing age and fibrosis stage. Our findings support early DAA therapy for all HCV infected individuals using DAA regimens recommended by current guidelines to optimize treatment outcomes .
- ritonavir / Generic mfg.
[VIRTUAL] PROGRESS TOWARDS ELIMINATION GOALS: UNMET NEEDS TO EVALUATE CURRENT HEPATITIS C INFECTION IN SINGLE CENTER () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1168;
High SVR rates were achieved overall (89.7%). Patients with cirrhosis require long-term regular follow-up for surveillance of HCC .
- Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead
[VIRTUAL] PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE DOCUMENTATION IN HEPATITIS C PATIENTS TREATED IN A TERTIARY CARE OUTPATIENT CLINIC SERVING RURAL AND URBAN KENTUCKY () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1167;
Innovative strategies to increase the disappointingly low SVR documentation rate are needed . Educational and motivational interventions should be developed to target in particular young and male patients who are at highest risk of not returning to check for cure .
- Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
[VIRTUAL] PARTNERSHIPS FOR ELIMINATION: AMBULATORY CARE CLINICAL PHARMACISTS DISMANTLING BARRIERS TO HEPATITIS C CURE () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1165;
Treatment breakdown was: 29 (76.3%) glecaprevir/ pibrentasvir, 6 (15.8%) sofosbuvir/velpatasvir & 3 (7.9%) ledipasvir/sofosbuvir. Integration of clinical pharmacist services within the VH program has contributed to the team based approach in dismantling barriers of HCV cure, including cost and access, drug interactions, adverse reactions, specialist requirements and nonadherence .
- Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
[VIRTUAL] HEPATITIS C TREATMENT IN THE UNITED STATES, 2014–2020 () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1158;
This average number of persons living with hepatitis C treated is below the number needed to ensure elimination of hepatitis C as a public health threat in the United States by 2030. Public health interventions such as increased testing and improved linkage to care for groups experiencing disproportionate impact, and removal of restrictions to treatment are critical to improve access to treatment and eliminate hepatitis C as a public health threat in the United States .
- [VIRTUAL] TRENDS IN HEPATOCELLULAR CARCINOMA AND ANTIVIRAL HEPATITIS TREATMENT IN OLDER AMERICANS () - Oct 21, 2021 - Abstract #AASLD2021AASLD_913;
Despite a marked increase in the effectiveness and frequency of HCV treatment in 2014 and 2015, HCV-attributable HCC continued to rise through 2015. Future studies should examine the incidence of HCV-attributable HCC among older Americans in subsequent years to assess the effect of the introduction of DAA therapies for HCV in this population .
- || ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal: Occurrence and recurrence of hepatocellular carcinoma in patients with HCV genotype 1b related cirrhosis treated with Ledipasvir + Sofosbuvir ± Ribavirin. (Pubmed Central) - Oct 14, 2021
Future studies should examine the incidence of HCV-attributable HCC among older Americans in subsequent years to assess the effect of the introduction of DAA therapies for HCV in this population . No abstract available
- || ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal, Combination therapy, Real-world evidence: Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience. (Pubmed Central) - Oct 14, 2021
LDV/SOF or PrOD±RBV were effective and tolerable treatments for patients with CHC and with or without advanced liver disease before and after liver transplantation. Although HCV eradication improves the liver function, there is a risk of developing HCC.